Journal of Peking University(Health Sciences) >
Predictive value of four items of new thrombus markers combined with conventional coagulation tests for thrombosis in antiphospholipid syndrome
Received date: 2023-08-20
Online published: 2023-12-11
Supported by
Beijing Municipal Science and Technology Projects(Z191100006619110)
Objective: To explore the predictive value of four items of new thrombus markers combined with conventional coagulation tests for thrombosis in antiphospholipid syndrome. Methods: A total of 121 antiphospholipid syndrome (APS) patients who hospitalized at Peking University People's Hospital from March 2022 to January 2023 were selected and divided into thrombus group (50 cases) and nonthrombus group (71 cases) according to whether thrombosis occurred. The differences of laboratory characteristics including antiphospholipid antibodies were compared between the thrombotic and non-thrombotic groups. Chemiluminescent immunoassay was used to detect thrombomodulin (TM), thrombin-antithrombin complex (TAT), Plasmin-α2 plasmin inhibitor complex (PIC), and tissue plasminogen activator inhibitor complex (t-PAIC) in plasma from venous. The independent risk factors of thrombosis in patients with APS were determined using binary Logistic regression. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the efficacy of each index on the prediction of thrombosis. Results: Compared with the patients without thrombosis, the patients with thrombosis were older [49 (32, 64) years vs. 36 (32, 39) years, P < 0.05]. The percentages of male, smoking, hypertension, and global antiphospholipid syndrome score (GAPSS)≥10 in the patients with thrombosis were significantly higher than those in the patients without thrombosis (P < 0.05). The positive rates of anticardiolipin antibody (aCL) and lupus anticoagulant (LA) in the thrombotic group were significantly higher than those in the non-thrombotic group (P < 0.05), and the levels of prothrombin time, activated partial thromboplastin time, fibrinogen, fibrin degradation product in the thrombotic group were significantly higher than those in the non-thrombotic group (P < 0.05).Among the thrombosis group, venous thrombosis accounted for 19 (38.00%), including deep vein thrombosis (16, 84.21%) and pulmonary embolism accounted (5, 26.32%); Arterial thrombosis accounted for 35 (70.00%), including myocardial infarction (6, 17.14%) cerebral infarction (30, 85.71%). The patients in the thrombotic group had significantly greater TM levels than those in the non-thrombotic group (P < 0.05).There were no significant dif-ferences between the two groups in TAT (Z=-1.420, P=0.156), PIC (Z=-0.064, P=0.949), and t-PAIC (Z=-1.487, P=0.137). Univariate and binary Logistic regression analysis of relevant variables showed that advanced age [OR=1.126, P=0.002], elevated TM [OR=1.325, P=0.048], prolonged prothrombin time (PT) [OR=4.127, P=0.008] were independent risk factors for thrombosis in the patients with APS. ROC curve analysis of the above three independent risk factors showed that the combined detection of age, PT and TM had the highest Yoden index (0.727) and sensitivity (83.0%), with a specificity of 89.7%. Conclusion: TAT, PIC, TM, and t-PAIC may reflect thrombus formation from the coagulation system, fibrinolysis system, and endothelial system. The combined of age TM and PT is superior to the application of a single marker, which has diagnostic value for the early identification of APS thrombosis.
Li-rong HONG , Yu-jia CHEN , Qing-lai JIANG , Ru-lin JIA , Chun LI , Liang-hua FENG . Predictive value of four items of new thrombus markers combined with conventional coagulation tests for thrombosis in antiphospholipid syndrome[J]. Journal of Peking University(Health Sciences), 2023 , 55(6) : 1033 -1038 . DOI: 10.19723/j.issn.1671-167X.2023.06.012
| 1 | Miyakis S , Lockshin MD , Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4 (2): 295- 306. |
| 2 | Galli M , Luciani D , Bertolini G , et al. Anti-β2-glycoprotein Ⅰ, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome[J]. Blood, 2003, 102 (8): 2717- 2723. |
| 3 | Cervera R , Serrano R , Pons-Estel GJ , et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1 000 patients[J]. Ann Rheum Dis, 2015, 74 (6): 1011- 1018. |
| 4 | 徐文龙, 沙宇. 血栓分子标志物联合Caprini评分预测创伤性下肢骨折后深静脉血栓形成风险研究[J]. 中国卫生检验杂志, 2023, 33 (2): 245-248, 257. |
| 5 | Zhao X , Yang S , Lei R , et al. Clinical study on the feasibility of new thrombus markers in predicting massive cerebral infarction[J]. Front Neurol, 2022, 13, 942887. |
| 6 | Tonello M , Mattia E , Favaro M , et al. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers[J]. Thromb Res, 2019, 177, 157- 160. |
| 7 | Schaller J , Gerber SS . The plasmin-antiplasmin system: structural and functional aspects[J]. Cell Mol Life Sci, 2011, 68 (5): 785- 801. |
| 8 | Salet DM , Bekkering S , Middeldorp S , et al. Targeting thromboinflammation in antiphospholipid syndrome[J]. J Thromb Haemost, 2023, 21 (4): 744- 757. |
| 9 | Zhou K , Zhang J , Zheng ZR , et al. Diagnostic and prognostic value of TAT, PIC, TM, and t-PAIC in malignant tumor patients with venous thrombosis[J]. Clin Appl Thromb Hemost, 2020, 26, 1- 10. |
| 10 | Wang L , Zhong J , Xiao D , et al. Thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2-plasmininhibitor complex (PIC), and tissue plasminogen activator-inhibitor complex (t-PAIC) assessment of fibrinolytic activity in postpartum hemorrhage: A retrospective comparative cohort study[J]. Ann Transl Med, 2022, 10 (23): 1273. |
| 11 | Loghmani H , Conway EM . Exploring traditional and nontraditional roles for thrombomodulin[J]. Blood, 2018, 132 (2): 148- 158. |
| 12 | Pletsch-Borba L , Grafetstatter M , Husing A , et al. Vascular injury biomarkers and stroke risk: A population-based study[J]. Neurology, 2020, 94 (22): e2337- e2345. |
| 13 | Kamtchum-Tatuene J , Mwangalika Kachingwe G , Mwandumba HC , et al. Endothelial dysfunction and carotid atherosclerosis in Malawian adults: A cross-sectional study[J]. eNeurologicalSci, 2020, 20, 100252. |
| 14 | Gosselin RC . An acute need inspiration: Autoneutralization of lupus anticoagulants in affected prothrombin times (PT) and activated partial thromboplastin times (APTT)[J]. Methods Mol Biol, 2023, 2663, 289- 295. |
| 15 | Fei Y , Tang N , Zhang H , et al. Significantly prolonged prothrombin time and activated partial thromboplastin time with no bleeding tendency: A patient with lupus anticoagulant-hypoprothrombinemia syndrome positive for immunoglobulin M anti-phosphatidylserine/prothrombin complex antibodies[J]. Semin Thromb Hemost, 2020, 46 (4): 507- 511. |
| 16 | Erzen B , Sabovic M . In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction[J]. Heart Vessels, 2013, 28 (5): 570- 577. |
| 17 | Nordenhem A , Leander K , Hallqvist J , et al. The complex between tPA and PAI-1: Risk factor for myocardial infarction as studied in the SHEEP project[J]. Thromb Res, 2005, 116 (3): 223- 232. |
| 18 | Winter MP , Kleber ME , Koller L , et al. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction[J]. Thromb Haemost, 2017, 117 (3): 471- 478. |
| 19 | Lundbech M , Krag AE , Christensen TD , et al. Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients[J]. Thromb Res, 2020, 186, 80- 85. |
| 20 | Tao J , Guo X , Li D , et al. Increased level of thrombomodulin is associated with endothelial injury in patients with sepsis-induced disseminated intravascular coagulation[J]. Clin Lab, 2021, 67 (8): 1863- 1870. |
| 21 | Asanuma K , Nakamura T , Okamoto T , et al. Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma[J]. BMC cancer, 2022, 22 (1): 1075. |
| 22 | Guo X , Tao H , Li D , et al. The α2-plasmin inhibitor-plasmin complex is a potential biomarker of venous thromboembolism in orthopedic trauma patients[J]. Clin Lab, 2021, 67 (4): 1065- 1072. |
/
| 〈 |
|
〉 |